Glaxosmithkline | GSK - Ebitda

Stock Price
54.44
Daily Change
-4.68 -7.92%
Monthly
-8.13%
Yearly
45.44%
Q2 Forecast
53.52

Glaxosmithkline reported GBP4.75B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Aurora Cannabis CAD 18.48M 3.11M Dec/2025
Bausch Health Companies USD 986M 74M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
J&J USD 7.19B 2.32B Dec/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 4.77B 1.11B Dec/2025
Pacira USD 38.71M 10.65M Dec/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 90.82M 3.99M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Supernus Pharmaceuticals USD 48.5M 6.6M Dec/2025
Takeda JPY 448.13B 173.98B Dec/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Zoetis USD 1.04B 87M Sep/2025